BBOT to Participate in Upcoming Investor Healthcare Conferences

GlobeNewswire

Yesterday

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.

Details of the company’s participation are as follows:

Cantor Global Healthcare Conference 2026
Wednesday, September 9, 2026, at 9:45 a.m. ET

Citi's 2026 Biopharma Back to School Conference
Thursday, September 10, 2026, at 3:00 p.m. ET

Morgan Stanley 24th Annual Global Healthcare Conference
Tuesday, September 15, 2026, at 1:50 p.m. ET

Live webcasts of the presentations will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. Replays of the webcasts will be available for at least 90 days following the event.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

CONTACT: BBOT Contacts:

Investor Contact:
BBOT
Investors@BBOTx.com

Media Contact:
Inizio Evoke Comms
Jake.robison@inizioevoke.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/2664886917"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664886917\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664886917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664886917","market":"sh","top_or_hot":-1,"title":"BBOT to Participate in Upcoming Investor Healthcare Conferences","media":"GlobeNewswire","content":"<html><body><p>SOUTH SAN FRANCISCO, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BBOT\">BridgeBio Oncology Therapeutics, Inc</a>. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.</p> <p><strong>Details of the company’s participation are as follows:</strong></p> <ul type=\"disc\"><li><strong>Cantor Global Healthcare Conference 2026</strong><br/>Wednesday, September 9, 2026, at 9:45 a.m. ET</li></ul> <ul type=\"disc\"><li><strong>Citi's 2026 Biopharma Back to School Conference</strong><br/>Thursday, September 10, 2026, at 3:00 p.m. ET</li></ul> <ul type=\"disc\"><li><strong>Morgan Stanley 24th Annual Global Healthcare Conference</strong><br/>Tuesday, September 15, 2026, at 1:50 p.m. ET<br/></li></ul> <p>Live webcasts of the presentations will be accessible on the “<strong>Events</strong>” page of the BBOT website at <strong>https://investors.bbotx.com/news-events/events</strong>. Replays of the webcasts will be available for at least 90 days following the event.</p> <p><strong>About BBOT</strong><br/>BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit <strong>www.bbotx.com</strong> and follow us on <strong>LinkedIn</strong>.</p> <pre>CONTACT: BBOT Contacts:\n\nInvestor Contact:\nBBOT\nInvestors@BBOTx.com\n\nMedia Contact:\nInizio Evoke Comms\nJake.robison@inizioevoke.com</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MTIxMjM5ZTYtY2U0Mi00NGMxLTg3ZjItNjU3MGJkZWZkMjdkLTEzMTQwNDctMjAyNi0wOS0wMS1lbg==/tiny/TheRas-Inc-d-b-a-BridgeBio-Onc.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BBOT to Participate in Upcoming Investor Healthcare Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBBOT to Participate in Upcoming Investor Healthcare Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-09-02 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>SOUTH SAN FRANCISCO, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BBOT\">BridgeBio Oncology Therapeutics, Inc</a>. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.</p> <p><strong>Details of the company’s participation are as follows:</strong></p> <ul type=\"disc\"><li><strong>Cantor Global Healthcare Conference 2026</strong><br/>Wednesday, September 9, 2026, at 9:45 a.m. ET</li></ul> <ul type=\"disc\"><li><strong>Citi's 2026 Biopharma Back to School Conference</strong><br/>Thursday, September 10, 2026, at 3:00 p.m. ET</li></ul> <ul type=\"disc\"><li><strong>Morgan Stanley 24th Annual Global Healthcare Conference</strong><br/>Tuesday, September 15, 2026, at 1:50 p.m. ET<br/></li></ul> <p>Live webcasts of the presentations will be accessible on the “<strong>Events</strong>” page of the BBOT website at <strong>https://investors.bbotx.com/news-events/events</strong>. Replays of the webcasts will be available for at least 90 days following the event.</p> <p><strong>About BBOT</strong><br/>BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit <strong>www.bbotx.com</strong> and follow us on <strong>LinkedIn</strong>.</p> <pre>CONTACT: BBOT Contacts:\n\nInvestor Contact:\nBBOT\nInvestors@BBOTx.com\n\nMedia Contact:\nInizio Evoke Comms\nJake.robison@inizioevoke.com</pre> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MTIxMjM5ZTYtY2U0Mi00NGMxLTg3ZjItNjU3MGJkZWZkMjdkLTEzMTQwNDctMjAyNi0wOS0wMS1lbg==/tiny/TheRas-Inc-d-b-a-BridgeBio-Onc.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBOT","symbol_name":"BridgeBio Oncology Therapeutics, Inc","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354587/0/en/bbot-to-participate-in-upcoming-investor-healthcare-conferences.html","article_id":"2664886917","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664886917","pubTimestamp":1788293100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"Investor Contact:. Investors@BBOTx.com. Media Contact:. Inizio Evoke Comms. Jake.robison@inizioevoke.com","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBOT":"BridgeBio Oncology Therapeutics, Inc","BK4581":"高盛持仓","BK4139":"生物科技","XLV":"健康照护类股ETF-SPDR","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","XBI":"SPDR S&P Biotech ETF","HCSG":"Healthcare Svcs Group Inc","LABU":"三倍做多标普生物-Direxion","BK4137":"综合支持服务","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"BBOT 将参加即将举行的投资者医疗保健会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1.5,"LABU":0.6,"XLV":1.5,"XBI":0.6,"BBOT":1.5},"content_text":"SOUTH SAN FRANCISCO, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences. Details of the company’s participation are as follows: Cantor Global Healthcare Conference 2026Wednesday, September 9, 2026, at 9:45 a.m. ET Citi's 2026 Biopharma Back to School ConferenceThursday, September 10, 2026, at 3:00 p.m. ET Morgan Stanley 24th Annual Global Healthcare ConferenceTuesday, September 15, 2026, at 1:50 p.m. ET Live webcasts of the presentations will be accessible on the “Events” page of the BBOT website at https://investors.bbotx.com/news-events/events. Replays of the webcasts will be available for at least 90 days following the event. About BBOTBBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn. CONTACT: BBOT Contacts:\n\nInvestor Contact:\nBBOT\nInvestors@BBOTx.com\n\nMedia Contact:\nInizio Evoke Comms\nJake.robison@inizioevoke.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}